381 related articles for article (PubMed ID: 16360023)
1. Big Pharma's Commedia.
Steele FR
Cell; 2005 Dec; 123(6):971-3. PubMed ID: 16360023
[No Abstract] [Full Text] [Related]
2. Wisdom from big pharma's Dr. Gloom. Interview by Abrahm Lustgarten.
Garnier JP
Fortune; 2005 Mar; 151(6):38. PubMed ID: 15782880
[No Abstract] [Full Text] [Related]
3. Pharma's year of trouble and strife.
Frantz S
Nat Rev Drug Discov; 2006 Jan; 5(1):7-9. PubMed ID: 16485339
[No Abstract] [Full Text] [Related]
4. IT solutions for big Pharma's big headache.
Krohn R
J Healthc Inf Manag; 2005; 19(1):13-5. PubMed ID: 15682670
[No Abstract] [Full Text] [Related]
5. Maturing biotechs turn to pharma's markets.
Ratner M
Nat Biotechnol; 2005 Mar; 23(3):269. PubMed ID: 15765067
[No Abstract] [Full Text] [Related]
6. Market watch: Upcoming catalysts in Q3 2014.
Haggerty R
Nat Rev Drug Discov; 2014 Jul; 13(7):486. PubMed ID: 24981351
[No Abstract] [Full Text] [Related]
7. Update of FDA's Critical Path Initiative.
Khleif S
Clin Adv Hematol Oncol; 2009 Mar; 7(3):173-4. PubMed ID: 19398939
[No Abstract] [Full Text] [Related]
8. Clinical research: outlook from industry.
Echols R
Clin Perform Qual Health Care; 1996; 4(2):113-4. PubMed ID: 10156942
[No Abstract] [Full Text] [Related]
9. A place in the sun.
Abbott A
Nature; 2007 Mar; 446(7132):124-5. PubMed ID: 17344823
[No Abstract] [Full Text] [Related]
10. Opinion: anticipating change in drug development: the emerging era of translational medicine and therapeutics.
Fitzgerald GA
Nat Rev Drug Discov; 2005 Oct; 4(10):815-8. PubMed ID: 16224453
[TBL] [Abstract][Full Text] [Related]
11. Biotech jostles with pharma for slice of HIV market.
Katsnelson A
Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
[No Abstract] [Full Text] [Related]
12. How will biotechnology fare in pharma's big plan?
Nat Biotechnol; 1996 Nov; 14(11):1515. PubMed ID: 9634811
[No Abstract] [Full Text] [Related]
13. Drug development and the FDA's Critical Path Initiative.
Woosley RL; Cossman J
Clin Pharmacol Ther; 2007 Jan; 81(1):129-33. PubMed ID: 17186012
[TBL] [Abstract][Full Text] [Related]
14. Bad medicine. Big Pharma's cash injections lead to poor ethical outcomes.
Sloane T
Mod Healthc; 2006 Aug; 36(31):19. PubMed ID: 16958350
[No Abstract] [Full Text] [Related]
15. Therapeutic success via targeted approaches and strategic partnerships with clinical laboratories.
Miller GA
IDrugs; 2007 Mar; 10(3):181-4. PubMed ID: 17351872
[TBL] [Abstract][Full Text] [Related]
16. Big pharma's struggles might benefit health plans.
Manag Care; 2012 Jan; 21(1):65. PubMed ID: 22334941
[No Abstract] [Full Text] [Related]
17. Redesigner drugs.
Dove A
Nat Biotechnol; 2004 Aug; 22(8):953-7. PubMed ID: 15286643
[TBL] [Abstract][Full Text] [Related]
18. Recombinant protein therapeutics--success rates, market trends and values to 2010.
Pavlou AK; Reichert JM
Nat Biotechnol; 2004 Dec; 22(12):1513-9. PubMed ID: 15583654
[No Abstract] [Full Text] [Related]
19. Pharma's commitment to maintaining a clinical trial register: increased transparency or contrived public appeasement?
Falit B
J Law Med Ethics; 2005; 33(2):391-6. PubMed ID: 16083099
[No Abstract] [Full Text] [Related]
20. The NIH, research institutions and industry: working together on a shared goal.
Omary MB
Gastroenterology; 2007 May; 132(5):1647-50. PubMed ID: 17484859
[No Abstract] [Full Text] [Related]
[Next] [New Search]
